Atea Pharmaceuticals Q2 Earnings Call Highlights
Yahoo Finance · Aug 12, 2026 · Atea Pharmaceuticals Inc (AVIR)
Atea Pharmaceuticals (NASDAQ:AVIR) reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C virus, saying the study met its primary and secondary endpoints against the standard-of-care regimen sofosbuvir/velpatasvir, marketed as Epclusa.
Not investment advice. Headline and summary only, not a full reprint.